h-hydrogen

Background: The utility of carcinoembryonic antigen (CEA) and carbohydrate antigen 15.3 (CA 15.3) as prognostic factors in pre-eminent titty cancer is unclear.

Methods: We prospectively wilful CEA and CA 15.3 in the sera of 2062 patients with untreated make bosom cancer diagnosed interceder 1984 and 2008.

Results: Increased CEA (>5 µg/L) and CA 15.3 (>30 kU/L) concentrations were develop in 12.7% and 19.6% of the patients, respectively, and 1 or both tumor markers were increased in 28% (570 of 2062). Increases in each tumor marker correlated with larger tumor sizes and nodal involvement. Tumor size, estrogen receptor (ER), and CEA were nonconformist prognostic factors by multivariate investigation in the mount up to assemblage [disease free survival (DFS) and all-inclusive survival (OS)] as all right as in node-positive (NP) and node-negative (NN) patients. Nodal involvement and histological rank were disconnected prognostic factors in the mount up to group as well as in NP patients. By contrast, adjuvant treatment and CA 15.3 were uncontrolled prognostic factors alone in NN patients (DFS and OS). All patients with CEA >7.5 µg/L had recurrence during follow-up. Use of both tumor markers allowed inequity of the groups of risk in T1 NN patients: 56.3% of recurrences were seen when 1 or both tumor markers were increased, whereas barely 9.4% of recurrences were seen in T1 NN patients without increases of either marker.

Conclusions: CEA and CA 15.3 are helpful prognostic factors in NP and NN titty cancer patients. CEA >7.5 µg/L is associated with a high presumption of subclinical metastases.